Colorado Psychedelics Activists Unite Behind Novem
Post# of 341
(Total Views: 207)
Posted On: 03/23/2022 4:41:19 PM
Colorado Psychedelics Activists Unite Behind November Ballot Measure
Activists in Colorado have decided to proceed with a single proposal to legalize psilocybin. This proposal, which is one of the quartet of psychedelic reform ballot measures drafted and filed for this year’s ballot, will also offer a pathway for the sealing of prior conviction records and establish healing centers where individuals can use psilocybin for therapeutic purposes.
The measure, known as Initiative 58, would also allow regulators to decide whether to legalize mescaline, ibogaine and DMT. Veronica Perez and Kevin Matthews, who managed the campaign behind Denver’s historic vote to locally decriminalize psilocybin in 2019, are the brains behind this measure. In an interview, Matthews explained that Initiative 58 was chosen because it was a comprehensive policy that would ensure that all the residents of Colorado have the option to access these natural medicines. He added that supporters were excited to start gathering signatures from voters, which would allow the proposal to appear on the coming ballot.
Under the measure, the Department of Regulatory Agencies would be in charge of the development of regulations for a therapeutic psychedelics program where individuals aged 21 and above could visit a licensed healing center to receive treatment under the supervision of a trained practitioner.
RBI Strategies’ Rick Ridder added that the reform’s approval and enactment would also help address mental health issues such as anxiety, addiction, trauma and depression.
The Decriminalize Nature chapter of Colorado is also running a separate campaign for statewide psychedelics reform. The chapter’s measure would decriminalize entheogenic fungi and plants in the state and allow individuals aged 21 and above to deliver, gift, grow and possess DMT, psilocybin, mescaline, ibogaine and psilocin. The campaign would also make it lawful to carry out psychedelics services for spiritual purposes, harm reduction, therapy and guidance, with or without accepting pay for the services rendered. However, the measure highlights that the sale of psychedelics would not be legal.
Colorado is one of the many states advocating for psychedelic reform in the country. For instance, the House of Representatives in Oklahoma approved a measure last week that would promote research into the therapeutic potential of psilocybin and decriminalize low-level possession of the psychedelic.
Additionally, the Hawaii Senate recently passed a resolution aimed to establish a state working group to conduct research on the therapeutic benefits of hallucinogenic mushrooms and come up with a plan to ensure that psilocybin was accessible for medical use by those aged 21 and above.
As these winds of change in favor of psychedelics blow across the nation, biopharm companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) are also doing whatever they can to bring to market psychedelic-based pharmaceutical formulations that are approved by the FDA and other regulators around the world.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Activists in Colorado have decided to proceed with a single proposal to legalize psilocybin. This proposal, which is one of the quartet of psychedelic reform ballot measures drafted and filed for this year’s ballot, will also offer a pathway for the sealing of prior conviction records and establish healing centers where individuals can use psilocybin for therapeutic purposes.
The measure, known as Initiative 58, would also allow regulators to decide whether to legalize mescaline, ibogaine and DMT. Veronica Perez and Kevin Matthews, who managed the campaign behind Denver’s historic vote to locally decriminalize psilocybin in 2019, are the brains behind this measure. In an interview, Matthews explained that Initiative 58 was chosen because it was a comprehensive policy that would ensure that all the residents of Colorado have the option to access these natural medicines. He added that supporters were excited to start gathering signatures from voters, which would allow the proposal to appear on the coming ballot.
Under the measure, the Department of Regulatory Agencies would be in charge of the development of regulations for a therapeutic psychedelics program where individuals aged 21 and above could visit a licensed healing center to receive treatment under the supervision of a trained practitioner.
RBI Strategies’ Rick Ridder added that the reform’s approval and enactment would also help address mental health issues such as anxiety, addiction, trauma and depression.
The Decriminalize Nature chapter of Colorado is also running a separate campaign for statewide psychedelics reform. The chapter’s measure would decriminalize entheogenic fungi and plants in the state and allow individuals aged 21 and above to deliver, gift, grow and possess DMT, psilocybin, mescaline, ibogaine and psilocin. The campaign would also make it lawful to carry out psychedelics services for spiritual purposes, harm reduction, therapy and guidance, with or without accepting pay for the services rendered. However, the measure highlights that the sale of psychedelics would not be legal.
Colorado is one of the many states advocating for psychedelic reform in the country. For instance, the House of Representatives in Oklahoma approved a measure last week that would promote research into the therapeutic potential of psilocybin and decriminalize low-level possession of the psychedelic.
Additionally, the Hawaii Senate recently passed a resolution aimed to establish a state working group to conduct research on the therapeutic benefits of hallucinogenic mushrooms and come up with a plan to ensure that psilocybin was accessible for medical use by those aged 21 and above.
As these winds of change in favor of psychedelics blow across the nation, biopharm companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) are also doing whatever they can to bring to market psychedelic-based pharmaceutical formulations that are approved by the FDA and other regulators around the world.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)